Literature DB >> 11689198

The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action.

R Jarzyna1, A Kiersztan, O Lisowa, J Bryła.   

Abstract

The effect of chloroquine on gluconeogenesis in isolated hepatocytes and kidney-cortex tubules of rabbit has been studied. The inhibitory action of 200 microM chloroquine was the highest in hepatocytes and renal tubules incubated with glutamine and glutamate+glycerol+octanoate, respectively, while in the presence of other substrates the drug action was less pronounced. With amino acids as substrates, the inhibition of gluconeogenesis was accompanied by a decreased glutamine production, resulting from a decline of glutamate dehydrogenase activity. A decrease in the urea production by hepatocytes incubated with chloroquine in the presence of glutamine but not NH4Cl as the source of ammonium is in agreement with this suggestion. The degree of inhibition by chloroquine of the rate of gluconeogenesis in renal tubules isolated from control rabbits was similar to that determined in diabetic animals. Chloroquine-induced changes in levels of intracellular gluconeogenic intermediates indicate a decrease in phosphoenolpyruvate carboxykinase and glucose-6-phosphatase activities probably due to increased concentration of 2-oxoglutarate, an inhibitor of these two enzymes. In view of the data, it is likely that inhibition by chloroquine of glucose formation in liver and kidney may contribute to the hypoglycaemic action of this drug. The importance of the inhibitory effect of chloroquine on glutamate dehydrogenase activity in the antihyperglycaemic action of the drug is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689198     DOI: 10.1016/s0014-2999(01)01221-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Hydroxychloroquine: a diabetic drug in disguise?

Authors:  Lydia Kang; Ted R Mikuls; James R O'Dell
Journal:  BMJ Case Rep       Date:  2009-03-02

2.  Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine.

Authors:  A Kiersztan; K Winiarska; J Drozak; M Przedlacka; M Wegrzynowicz; T Fraczyk; J Bryla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

3.  Diabetes-induced changes in glucose synthesis, intracellular glutathione status and hydroxyl free radical generation in rabbit kidney-cortex tubules.

Authors:  K Winiarska; J Drozak; M Wegrzynowicz; T Fraczyk; J Bryla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

4.  Chloroquine differentially modulates coronary vasodilation in control and diabetic mice.

Authors:  Qian Zhang; Atsumi Tsuji-Hosokawa; Conor Willson; Makiko Watanabe; Rui Si; Ning Lai; Ziyi Wang; Jason X-J Yuan; Jian Wang; Ayako Makino
Journal:  Br J Pharmacol       Date:  2020-01-08       Impact factor: 8.739

5.  The Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley Rats.

Authors:  Happiness P Sibiya; Musa V Mabandla; Cephas T Musabayane
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

6.  Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Authors:  Ciska Verbaanderd; Hannelore Maes; Marco B Schaaf; Vikas P Sukhatme; Pan Pantziarka; Vidula Sukhatme; Patrizia Agostinis; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2017-11-23

7.  A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.

Authors:  Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

9.  Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling.

Authors:  Ivan Nemazanyy; Guillaume Montagnac; Ryan C Russell; Lucille Morzyglod; Anne-Françoise Burnol; Kun-Liang Guan; Mario Pende; Ganna Panasyuk
Journal:  Nat Commun       Date:  2015-09-21       Impact factor: 14.919

10.  Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Authors:  Remco J Molenaar; Robert J S Coelen; Mohammed Khurshed; Eva Roos; Matthan W A Caan; Myra E van Linde; Mathilde Kouwenhoven; Jos A M Bramer; Judith V M G Bovée; Ron A Mathôt; Heinz-Josef Klümpen; Hanneke W M van Laarhoven; Cornelis J F van Noorden; W Peter Vandertop; Hans Gelderblom; Thomas M van Gulik; Johanna W Wilmink
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.